Le CompaGnon Part 2
Wednesday June 22, 2016
From the American Society of Clinical Oncology (ASCO)
- Checkpoint inhibitors
- the CAR T Approach
- Adoptive cell therapy
- Oncolytic virus therapy
- Therapeutic vaccines
Le CompaGnon Part 1 dealt with:
- The two firms, MERK and BMY, who were the first to get approvals of their checkpoint inhibitors. These two . . .
This content is for paid subscribers.
Prohost Letters June 23, 2016